PR95662

SHENZHEN, China, April 26, 2022 /PRNewswire=KYODO JBN/ --

SonoScape Medical Corp. today announced the release of S-Fetus 4.0, the latest

software upgrade of the company's flagship ultrasound product offering. This

technical breakthrough marks S-Fetus 4.0 as the globally first smart obstetric

screening technology based on deep learning.

Leveraging the deep learning techniques, the S-Fetus 4.0 Obstetric Screening

Assistant allows doctors to automatically acquire standard planes and measure

fetal biometry with fast performance and accuracy. Without the need for

manually repetitive operation of the device, the system was designed with

one-click simple touch to streamline the sonogram pocess and improve scanning

efficiency. "Our obstetric screening assistant has achieved breakthroughs in

terms of performance and scalability and now it can offer more efficient means

of smart obstetric diagnosis that assist doctors in precise work to ensure

better patient outcomes", said Zhou Guoyi, Head of SonoScape Medical Innovation

Research Center.

To improve service capability, SonoScape applied this newly upgrade to a

variety of high-end ultrasound equipment. The S-Fetus 4.0 is going to run on

SonoScape S60, P60, P60 Exp, S50 Elite, P50 Elite and P40 Elite, both in the

North America and ROW Region. "With our commitment to the independent R&D and

innovation of medical equipment, our cutting edge technology has been able to

realize its potential to serve medical institutions around the world",

commented Naizhang Feng, Vice President of SonoScape Ultrasound Division.

The S-Fetus 4.0 Obstetric Screening Assistant is powered by Intel® oneAPI

Toolkits, for more information please check

https://www.intel.com/content/www/us/en/healthcare-it/resources/sonoscape-oneapi-brief.html

About SonoScape

Founded in 2002 in Shenzhen China, SonoScape has committed itself to "Caring

for Life through Innovation" by providing ultrasound and endoscopy solutions.

With seamless support, SonoScape provides worldwide sales and service in more

than 130 countries, benefiting local hospitals and doctors with comprehensive

imaging diagnostic evidence and technical support. Investing 20% of total

revenue into R&D annually, SonoScape establishes seven R&D centers in Shenzhen,

Shanghai, Harbin, Wuhan, Tokyo, Seattle, and Silicon Valley, with more advanced

products to be introduced into the pipeline.

For more information, please visit us at https://sonoscape.com/.

SOURCE  SonoScape Medical Corporation

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=419948

   Caption: SonoScape S-Fetus 4.0 Obstetric Screening Assistant